Hemostatic complications of hematopoietic stem cell transplantation: From hemorrhage to microangiopathies and VOD

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue SUPPL. 1, 2003, Pages 50-53

  Richardson, Paul ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEFIBROTIDE; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; NITROSOUREA; PLATINUM DERIVATIVE; THROMBOCYTE CONCENTRATE;

BLEEDING; CONFERENCE PAPER; CYTOTOXICITY; HEMATOPOIETIC STEM CELL; HEMOSTASIS; HUMAN; MICROANGIOPATHY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; UREMIA;

ANEMIA, HEMOLYTIC; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS;

EID: 0344497387     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073293     Document Type: Conference Paper

References (30)

1. Beutler E: Platelet transfusions: The 20,000/μL trigger. Blood 1993;81:1411-1413.
2. Heal JM, Blumberg N, Masel D: An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987;709:23-30.
3. Lee EJ, Schiffer CA: ABO compatibility can influence the results of platelet transfusion: Results of a randomized trial. Transfusion 1989;29:384-389.
4. Junghans RP, Ahn YS: High-dose intravenous gammaglobulin to suppress alloimmune destruction of donor platelets. AM J Med 1994;73:204-208.
5. Schiffer CA, Hogge DE, Aisner J, et al: High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood 1984;64:937-940.
6. The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation or platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-1869.
7. Heddle NM, Blajchman MA: The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusion. Blood 1995;85:603-606.
8. Kaushansky K: Thrombopoietin: Platelets on demand? Ann Intern Med 1997;126:731-733.
9. National Institutes of Health Consensus Conference: Fresh frozen plasma: Indications and risks. JAMA 1985;253:551-553.
10. American Association of Blood Banks: Standards for Blood Banks and Transfusion Services, ed 16. Bethesda, Maryland, 1994.
11. Pettit AR, Clark RE: Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994;14:495-504.
12. Holler E, Kolb JH, Hiller F, et al: Microangiopathy in patients on cyclosporine prophylaxis who develop acute graft-versus-host disease after HLA identical bone marrow transplantation. Blood 1989;73:2018-2024.
13. Zeigler ZR, Rosenfeld CS, Andrews DF, et al: Plasma von Willebrand factor antigen (vWF:AG) and thrombomodulin (TM) levels in adult thrombotic thrombocytopenic purpura/hemolytic uremic syndromes (TTP/HUS). Am J Hematol 1996;53:213-220.
14. Rock GA, Shumak KH, Buskand NA, et al: Comparison of plasma exchange with plasma infusion in the treatment of thrombocytopenic purpura. N Engl J Med 1991;325:393-403.
15. Shaw BE, Potter MN, Pawson R, Virchis AE, Patch D, Murphy K, Perry D, Prentice HG: The use of Defibrotide in the management of vascular endothelial complications (VOD/HUS/TTP) of stem cell transplantation. Blood 1999;96(10):608a.
16. Srivastava A, Gottlieb D, Bradstock KF: Diffuse alveolar hemorrhage associated with micro-angiopathy after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15:863-867.
17. McDonald GB, Hinds MS, Fisher LD, et al: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993;118:255-267.
18. Carreras E, Bertz H, Arcese W, et al., European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party: Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. Blood 1998;92:3599-3604.
19. Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB: Veno-occlusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology 1994;19:1171-1181.
20. Vannucchi AM, Rafanelli D, Longo G, et al: Early hemostatic alterations following bone marrow transplantation: A prospective study. Haematologica 1994;79:519-525.
21. Faioni EM, Mannucci PM: Veno-occlusive disease of the liver after bone marrow transplantation: The role of hemostasis. Leuk Lymphoma 1997;25:233-245.
22. Catani L, Gugliotta L, Vianelli N, et al: Endothelium and bone marrow transplantation. Bone Marrow Transplant 1996;17:277-280.
23. Salat C, Holler E, Kolb HJ, et al: Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997;89:2184-2188.
24. Ringden O, Ruutu T, Remnerger M, et al: A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group. Blood 1994;83:2723-2730.
25. Bearman SI, Lee JL, Baron AE, McDonald GB: Treatment of hepatic veno-occlusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997;89:1501-1506.
26. Richardson PG, Elias AD, Krishnan A, et al: Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population. Blood 1998;92:737-744.
27. Chopra R, Eaton JD, Grassi A, et al: Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study. Br J Haematol 2000;111:1122-1129.
28. Falanga A, Vignoli A, Marchetti M, Barbui T: Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003;17:1636-1642.
29. Richardson PG, Murakami C, Jin Z, et al: Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100:4337-4343.
30. Ringdén O, Remberger M, Lehmann S, et al: N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2000;111:1122-1129.